Switch theme
Sign up to access all valuation multiples
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
1991
19.5K+
LTM Revenue $1.5B
LTM EBITDA $373M
$12.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mankind Pharma has a last 12-month revenue (LTM) of $1.5B and a last 12-month EBITDA of $373M.
In the most recent fiscal year, Mankind Pharma achieved revenue of $1.4B and an EBITDA of $418M.
Mankind Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mankind Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5B | XXX | $1.4B | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $373M | XXX | $418M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $297M | XXX | $281M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $235M | XXX | $233M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $946M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mankind Pharma's stock price is INR 2474 (or $29).
Mankind Pharma has current market cap of INR 1.02T (or $12.0B), and EV of INR 1.08T (or $12.7B).
See Mankind Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.7B | $12.0B | XXX | XXX | XXX | XXX | $0.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mankind Pharma has market cap of $12.0B and EV of $12.7B.
Mankind Pharma's trades at 9.2x EV/Revenue multiple, and 31.9x EV/EBITDA.
Equity research analysts estimate Mankind Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mankind Pharma has a P/E ratio of 50.8x.
See valuation multiples for Mankind Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.0B | XXX | $12.0B | XXX | XXX | XXX |
| EV (current) | $12.7B | XXX | $12.7B | XXX | XXX | XXX |
| EV/Revenue | 8.5x | XXX | 9.2x | XXX | XXX | XXX |
| EV/EBITDA | 33.9x | XXX | 31.9x | XXX | XXX | XXX |
| EV/EBIT | 42.6x | XXX | 45.9x | XXX | XXX | XXX |
| EV/Gross Profit | 12.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 50.8x | XXX | 51.8x | XXX | XXX | XXX |
| EV/FCF | -18.2x | XXX | 58.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMankind Pharma's last 12 month revenue growth is 20%
Mankind Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $38K for the same period.
Mankind Pharma's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mankind Pharma's rule of X is 74% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mankind Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | 13% | XXX | XXX | XXX |
| Rule of 40 | 48% | XXX | 48% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 74% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $38K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mankind Pharma acquired XXX companies to date.
Last acquisition by Mankind Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Mankind Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mankind Pharma founded? | Mankind Pharma was founded in 1991. |
| Where is Mankind Pharma headquartered? | Mankind Pharma is headquartered in India. |
| How many employees does Mankind Pharma have? | As of today, Mankind Pharma has 19.5K+ employees. |
| Who is the CEO of Mankind Pharma? | Mankind Pharma's CEO is Mr. Sheetal Arora. |
| Is Mankind Pharma publicy listed? | Yes, Mankind Pharma is a public company listed on BOM. |
| What is the stock symbol of Mankind Pharma? | Mankind Pharma trades under 543904 ticker. |
| When did Mankind Pharma go public? | Mankind Pharma went public in 2023. |
| Who are competitors of Mankind Pharma? | Similar companies to Mankind Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Mankind Pharma? | Mankind Pharma's current market cap is $12.0B |
| What is the current revenue of Mankind Pharma? | Mankind Pharma's last 12 months revenue is $1.5B. |
| What is the current revenue growth of Mankind Pharma? | Mankind Pharma revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Mankind Pharma? | Current revenue multiple of Mankind Pharma is 8.5x. |
| Is Mankind Pharma profitable? | Yes, Mankind Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mankind Pharma? | Mankind Pharma's last 12 months EBITDA is $373M. |
| What is Mankind Pharma's EBITDA margin? | Mankind Pharma's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Mankind Pharma? | Current EBITDA multiple of Mankind Pharma is 33.9x. |
| What is the current FCF of Mankind Pharma? | Mankind Pharma's last 12 months FCF is -$695M. |
| What is Mankind Pharma's FCF margin? | Mankind Pharma's last 12 months FCF margin is -47%. |
| What is the current EV/FCF multiple of Mankind Pharma? | Current FCF multiple of Mankind Pharma is -18.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
